Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hillel Panitch

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of the Neurological Sciences|September 20, 2005
Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trialHillel Panitch, Douglas Goodin, Gordon Francis, et al.
Archives of Neurology|May 11, 2005
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE StudySteven R Schwid, John Thorpe, Mohammad Sharief, et al.
Lancet (London, England)|August 16, 2005
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchangeMark Keegan, Fatima König, Robyn McClelland, et al.
Annals of Neurology|October 23, 2009
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialKathleen Hawker, Paul O'Connor, Mark S Freedman, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of the Neurological Sciences|September 20, 2005
Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trialHillel Panitch, Douglas Goodin, Gordon Francis, et al.
Archives of Neurology|May 11, 2005
Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE StudySteven R Schwid, John Thorpe, Mohammad Sharief, et al.
Lancet (London, England)|August 16, 2005
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchangeMark Keegan, Fatima König, Robyn McClelland, et al.
Annals of Neurology|October 23, 2009
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialKathleen Hawker, Paul O'Connor, Mark S Freedman, et al.
Pageof 2